Royalty Pharma plc
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the third quarter of 2026, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”):
| Name and Title | Action | Adoption/ TerminationDate | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|---|
| Chris HiteExecutive Vice President & Chairman, Partnering & Investments | Adoption | September 21, 2026 | March 12, 2027 | 323,200 |
| Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments | Adoption | August 7, 2026 | February 2, 2027 | 150,000 |
| Terrance CoyneExecutive Vice President & Chief Financial Officer | Adoption | August 6, 2026 | February 24, 2027 | 250,000 and EPA Shares(2) |
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2)Maximum shares subject to trading plan consists of up to 250,000 Class A ordinary shares and 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in November 2026 and February 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.